Reported Earnings • May 20
First quarter 2026 earnings released: JP¥1.14 loss per share (vs JP¥1.34 loss in 1Q 2025) First quarter 2026 results: JP¥1.14 loss per share. Revenue: JP¥6.00m (down 76% from 1Q 2025). Net loss: JP¥307.0m (loss widened 5.1% from 1Q 2025). New Risk • Apr 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Revenue is less than US$5m (JP¥429m revenue, or US$2.7m). Market cap is less than US$100m (JP¥10.1b market cap, or US$63.3m). Reported Earnings • Mar 29
Full year 2025 earnings released: JP¥3.69 loss per share (vs JP¥9.77 loss in FY 2024) Full year 2025 results: JP¥3.69 loss per share (improved from JP¥9.77 loss in FY 2024). Revenue: JP¥429.0m (up 36% from FY 2024). Net loss: JP¥876.0m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 16
Full year 2025 earnings released: JP¥3.69 loss per share (vs JP¥9.77 loss in FY 2024) Full year 2025 results: JP¥3.69 loss per share (improved from JP¥9.77 loss in FY 2024). Revenue: JP¥429.0m (up 36% from FY 2024). Net loss: JP¥876.0m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Feb 13
Solasia Pharma K.K., Annual General Meeting, Mar 25, 2026 Solasia Pharma K.K., Annual General Meeting, Mar 25, 2026. Announcement • Dec 18
Solasia Pharma K.K. to Report Fiscal Year 2025 Results on Feb 13, 2026 Solasia Pharma K.K. announced that they will report fiscal year 2025 results on Feb 13, 2026 New Risk • Aug 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Revenue is less than US$5m (JP¥293m revenue, or US$2.0m). Market cap is less than US$100m (JP¥9.72b market cap, or US$66.0m). Reported Earnings • Aug 15
Second quarter 2025 earnings released: JP¥1.20 loss per share (vs JP¥1.57 loss in 2Q 2024) Second quarter 2025 results: JP¥1.20 loss per share (improved from JP¥1.57 loss in 2Q 2024). Revenue: JP¥24.0m (down 60% from 2Q 2024). Net loss: JP¥263.0m (loss narrowed 12% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • May 20
First quarter 2025 earnings released: JP¥1.34 loss per share (vs JP¥1.78 loss in 1Q 2024) First quarter 2025 results: JP¥1.34 loss per share (improved from JP¥1.78 loss in 1Q 2024). Revenue: JP¥25.0m (up 127% from 1Q 2024). Net loss: JP¥292.0m (loss narrowed 5.8% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Announcement • Apr 10
Solasia Pharma K.K. announced that it has received ¥2.176 million in funding from Macquarie Group Limited On April 9, 2025, Solasia Pharma K.K. closed the transaction. Announcement • Mar 24
Solasia Pharma K.K. announced that it expects to receive ¥2.176 million in funding from Macquarie Group Limited Solasia Pharma K.K. announced a private placement to issue 544,000 Series 15 warrant at an issue price of ¥4 per warrant for gross proceeds of ¥2,176,000 on March 24, 2025. The transaction will include participation from new investor Macquarie Bank Limited. The transaction has been approved by shareholders, expected to close on April 9, 2025. The funding amount of the transaction is ¥2,069,376,000 (estimated amount of proceeds excluding costs: ¥2,049,376,000) and exercise price is ¥38. Reported Earnings • Feb 14
Full year 2024 earnings released: JP¥9.77 loss per share (vs JP¥6.61 loss in FY 2023) Full year 2024 results: JP¥9.77 loss per share (further deteriorated from JP¥6.61 loss in FY 2023). Revenue: JP¥316.0m (down 49% from FY 2023). Net loss: JP¥1.94b (loss widened 75% from FY 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Announcement • Feb 12
Solasia Pharma K.K., Annual General Meeting, Mar 26, 2025 Solasia Pharma K.K., Annual General Meeting, Mar 26, 2025. Announcement • Jan 06
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 Solasia Pharma K.K. revised consolidated earnings guidance for the fiscal year ending December 31, 2024. For the year, the company expects revenue to be JPY 300 million, operating loss to be JPY 1,050 million, loss attributable to owners of parent JPY 1,050 million or basic loss per share to be JPY 5.28 against pervious guidance of revenue to be JPY 160 million, operating loss to be JPY 1,150 million, loss attributable to owners of parent JPY 1,150 million or basic loss per share to be JPY 5.79. Announcement • Jan 03
Solasia Pharma K.K. to Report Fiscal Year 2024 Results on Feb 14, 2025 Solasia Pharma K.K. announced that they will report fiscal year 2024 results on Feb 14, 2025 New Risk • Nov 20
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: JP¥96m (US$621k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$1m (JP¥96m revenue, or US$621k). Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (JP¥9.58b market cap, or US$61.9m). Reported Earnings • Aug 19
Second quarter 2024 earnings released: JP¥1.58 loss per share (vs JP¥1.17 loss in 2Q 2023) Second quarter 2024 results: JP¥1.58 loss per share (further deteriorated from JP¥1.17 loss in 2Q 2023). Net loss: JP¥301.0m (loss widened 54% from 2Q 2023). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Reported Earnings • May 21
First quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥1.44 loss in 1Q 2023) First quarter 2024 results: JP¥1.78 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥11.0m (down 95% from 1Q 2023). Net loss: JP¥310.0m (loss widened 29% from 1Q 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 21 The analyst covering Solasia Pharma K.K previously expected the company to break even in 2026. New forecast suggests losses will reduce by 8.7% per year to 2025. The company is expected to make a profit of JP¥96.0m in 2026. Average annual earnings growth of 0.6% is required to achieve expected profit on schedule.
Announcement • May 16
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024 Solasia Pharma K.K. provided consolidated earnings forecasts for the fiscal year ending December 31, 2024. For the year, the company expects revenue to be in the range of JPY 1,250 million to JPY 1,500 million, operating loss to be in the range of JPY 800 million to JPY 550 million, loss to be in the range of JPY 800 million to JPY 550 million, loss attributable to owners of parent to be in the range of JPY 800 million to JPY 550 million and basic loss per share to be in the range of JPY 4.39 to JPY 3.02. Reported Earnings • Mar 28
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Full year 2023 results: JP¥6.61 loss per share (improved from JP¥16.77 loss in FY 2022). Revenue: JP¥617.0m (down 44% from FY 2022). Net loss: JP¥1.11b (loss narrowed 56% from FY 2022). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. New Risk • Mar 25
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: JP¥1.1b Forecast net loss in 1 year: JP¥538m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (JP¥538m net loss next year). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Revenue is less than US$5m (JP¥617m revenue, or US$4.1m). Market cap is less than US$100m (JP¥5.57b market cap, or US$36.8m). Announcement • Mar 05
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited On March 4, 2024, Solasia Pharma K.K. closed the transaction. Major Estimate Revision • Mar 05
Consensus EPS estimates fall by 36%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from JP¥1.54b to JP¥1.66b. Forecast EPS reduced from -JP¥2.28 to -JP¥3.09 per share. Biotechs industry in Japan expected to see average net income growth of 25% next year. Consensus price target of JP¥100.00 unchanged from last update. Share price was steady at JP¥37.00 over the past week. Breakeven Date Change • Mar 04
Forecast breakeven date pushed back to 2026 The analyst covering Solasia Pharma K.K previously expected the company to break even in 2025. New forecast suggests the company will make a profit of JP¥196.0m in 2026. Average annual earnings growth of 65% is required to achieve expected profit on schedule. Reported Earnings • Feb 17
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Full year 2023 results: JP¥6.61 loss per share (improved from JP¥16.77 loss in FY 2022). Revenue: JP¥617.0m (down 44% from FY 2022). Net loss: JP¥1.11b (loss narrowed 56% from FY 2022). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Announcement • Feb 16
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited Solasia Pharma K.K. announced a private placement of 40 1% series 3 unsecured non-convertible bonds at a price of ¥12,500,000 per bond for the gross proceeds of ¥500,000,000 and 433,000 14th stock acquisition rights at a price of ¥10 per warrant for the gross proceeds of ¥4,330,000 on February 15, 2024. The bonds carry a coupon rate of 1% per annum and is expected to close on March 4, 2024. The transaction has been approved by the shareholders of the company. The company expects estimated net proceeds ¥1,693,030,000 inclusive of amount raised by issuing stock acquisition rights ¥4,330,000 and amount raised by exercising stock acquisition rights ¥1,688,700,000. The bonds will mature on March 3, 2027 and warrant exercise price is ¥39. Announcement • Feb 14
Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024 Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024. New Risk • Jan 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (JP¥7.83b market cap, or US$53.0m). Major Estimate Revision • Jan 16
Consensus revenue estimates fall by 66% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from JP¥1.84b to JP¥631.0m. Forecast losses increased from -JP¥2.93 to -JP¥6.68 per share. Biotechs industry in Japan expected to see average net income growth of 36% next year. Consensus price target up from JP¥70.00 to JP¥100.00. Share price was steady at JP¥45.00 over the past week. New Risk • Jan 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥1.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risk Market cap is less than US$100m (JP¥7.07b market cap, or US$48.8m). Announcement • Dec 28
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 Solasia Pharma K.K. revised consolidated earnings guidance for the fiscal year ending December 31, 2023. For the year, the company now expects revenue of JPY 620 million, operating loss of JPY 1,150 million, loss attributable to owners of parent of JPY 1,150 million and basic loss per share of JPY 6.62 against previous forecast of revenue between JPY 1,000 million to JPY 1,800 million, operating loss between JPY 1,150 million to JPY 350 million, loss attributable to owners of parent between JPY 1,150 million to JPY 350 million and basic loss per share between JPY 6.85 to JPY 2.08. New Risk • Dec 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-JP¥1.2b). Market cap is less than US$100m (JP¥8.92b market cap, or US$60.9m). Reported Earnings • Nov 17
Third quarter 2023 earnings released: JP¥1.97 loss per share (vs JP¥4.95 loss in 3Q 2022) Third quarter 2023 results: JP¥1.97 loss per share (improved from JP¥4.95 loss in 3Q 2022). Revenue: JP¥73.0m (down 75% from 3Q 2022). Net loss: JP¥331.0m (loss narrowed 59% from 3Q 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 14
Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022) Second quarter 2023 results: JP¥1.17 loss per share (improved from JP¥4.38 loss in 2Q 2022). Revenue: JP¥309.0m (up 307% from 2Q 2022). Net loss: JP¥196.0m (loss narrowed 69% from 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥4.61 loss in 1Q 2022) First quarter 2023 results: JP¥1.44 loss per share (improved from JP¥4.61 loss in 1Q 2022). Revenue: JP¥220.0m (up 95% from 1Q 2022). Net loss: JP¥241.0m (loss narrowed 61% from 1Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Auditor Yoshiyuki Yamakawa was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Mar 28
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: JP¥16.77 loss per share. Revenue: JP¥1.09b (up 95% from FY 2021). Net loss: JP¥2.55b (loss widened 2.8% from FY 2021). Revenue exceeded analyst estimates by 40%. Earnings per share (EPS) missed analyst estimates by 7.3%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Japan. Reported Earnings • Feb 16
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: JP¥16.77 loss per share. Revenue: JP¥1.09b (up 95% from FY 2021). Net loss: JP¥2.55b (loss widened 2.8% from FY 2021). Revenue exceeded analyst estimates by 40%. Earnings per share (EPS) missed analyst estimates by 7.3%. Announcement • Feb 14
Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023 Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023. Announcement • Dec 06
Solasia Pharma K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023 Solasia Pharma K.K. announced that they will report fiscal year 2022 results on Feb 14, 2023 Reported Earnings • Nov 16
Third quarter 2022 earnings released: JP¥4.95 loss per share (vs JP¥5.46 loss in 3Q 2021) Third quarter 2022 results: JP¥4.95 loss per share. Revenue: JP¥296.0m (up JP¥291.0m from 3Q 2021). Net loss: JP¥802.0m (loss widened 12% from 3Q 2021). Buying Opportunity • Oct 28
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 46%. The fair value is estimated to be JP¥62.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 299% in 2 years. Earnings is forecast to grow by 78% in the next 2 years. Buying Opportunity • Oct 11
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 45%. The fair value is estimated to be JP¥63.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 299% in 2 years. Earnings is forecast to grow by 78% in the next 2 years. Buying Opportunity • Sep 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 30%. The fair value is estimated to be JP¥74.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 299% in 2 years. Earnings is forecast to grow by 78% in the next 2 years. Reported Earnings • Aug 17
Second quarter 2022 earnings released: JP¥4.38 loss per share (vs JP¥5.67 loss in 2Q 2021) Second quarter 2022 results: JP¥4.38 loss per share (up from JP¥5.67 loss in 2Q 2021). Revenue: JP¥76.0m (down 59% from 2Q 2021). Net loss: JP¥632.0m (loss narrowed 14% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 16
First quarter 2022 earnings released: JP¥4.61 loss per share (vs JP¥5.22 loss in 1Q 2021) First quarter 2022 results: JP¥4.61 loss per share (up from JP¥5.22 loss in 1Q 2021). Revenue: JP¥113.0m (up 24% from 1Q 2021). Net loss: JP¥615.0m (loss narrowed 6.2% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥19.04 loss per share (up from JP¥35.16 loss in FY 2020). Revenue: JP¥559.0m (up 23% from FY 2020). Net loss: JP¥2.48b (loss narrowed 40% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 9% per year. Reported Earnings • Feb 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥19.04 loss per share (up from JP¥35.16 loss in FY 2020). Revenue: JP¥559.0m (up 23% from FY 2020). Net loss: JP¥2.48b (loss narrowed 40% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 9% per year. Reported Earnings • Nov 11
Third quarter 2021 earnings released: JP¥5.46 loss per share (vs JP¥5.71 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥5.00m (down 89% from 3Q 2020). Net loss: JP¥717.0m (loss widened 7.8% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 13
Second quarter 2021 earnings released: JP¥5.67 loss per share (vs JP¥6.36 loss in 2Q 2020) The company reported a solid second quarter result with improved revenues and control over costs, although losses were not reduced. Second quarter 2021 results: Revenue: JP¥186.0m (up 121% from 2Q 2020). Net loss: JP¥738.0m (flat on 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 14
First quarter 2021 earnings released: JP¥5.22 loss per share (vs JP¥4.54 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: JP¥91.0m (down 42% from 1Q 2020). Net loss: JP¥656.0m (loss widened 24% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 02
Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: JP¥454.0m (down 65% from FY 2019). Net loss: JP¥4.13b (loss widened 121% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Announcement • Mar 04
Solasia Pharma K.K. to Report Q2, 2021 Results on Aug 11, 2021 Solasia Pharma K.K. announced that they will report Q2, 2021 results on Aug 11, 2021 
